Inhaled AAT
An investigational medicine for Alpha-1 Antitrypsin
Deficiency lung disease
Alpha-1 eficiency
Alpha-1 Antitrypsin Deficiency
(AATD) is a rare genetic condition
that increases the risk for lung
disease, liver disorders, and
panniculitis (a skin disease).
People with low levels of
Alpha-1 Antitrypsin may
be at risk of developing a
severe chronic lung
disease.
Alpha-1 Antitrypsin is a protein
produced in the liver and also in
other organs such as the lung. Its main role is to protect the lung
from being damaged during
inflammation.
To learn more about
Alpha-1 Antitrypsin
Deficiency, please visit the
Alpha-1 Foundation website
at: https://www.alpha1.org
AAT by inhalation
Administration of AAT by inhalation aims to replace the deficient Alpha-1
Antitrypsin protein in the lung.
Inhaled-AAT is an investigational
medicine. This means that it is not
yet approved for marketing and can
only be given within a clinical study.
Inhalation is a convenient,
non-invasive and widely used
therapeutic approach to deliver
medicines directly to the lungs.
Kamada has conducted several
clinical studies with Inhaled-AAT.
More than 200 patients have
received Inhaled-AAT in clinical
research settings.
Alpha-1 eficiency
Alpha-1 Antitrypsin Deficiency
(AATD) is a rare genetic condition that increases the risk for lung disease, liver disorders, and panniculitis (a skin disease).
People with low levels of Alpha-1 Antitrypsin may be
at risk of developing a
severe chronic lung disease.
Alpha-1 Antitrypsin is a
protein produced in the liver and also in other organs such as the lung. Its main role is
to protect the lung from being damaged during inflammation.
To learn more about
Alpha-1 Antitrypsin Deficiency, please visit the Alpha-1 Foundation website at: https://www.alpha1.org
AAT by inhalation
Administration of AAT by inhalation aims to replace the deficient Alpha-1 Antitrypsin protein in the lung.
Inhaled-AAT is an investigational medicine. This means that it is not yet approved for marketing and can only be given within a clinical study.
Inhalation is a convenient, non-invasive and widely used therapeutic approach to deliver medicines directly to the lungs.
Kamada has conducted several clinical studies with Inhaled-AAT. More than 200 patients have received Inhaled-AAT in clinical research settings.